Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Force Welath to hold a webinar » 11:45
01/12/21
01/12
11:45
01/12/21
11:45
CANF

Can-Fite BioPharma

$1.95 /

+0.045 (+2.36%)

Webinar entitled,…

Webinar entitled, "NASH: The Biggest Market Opportunity of 2021" consists of Can-Fite BioPharma's Dr. Fishman discussing NASH, Non-Alcoholic Fatty Liver Disease and Hepatitis C, its implications on public health and the opportunities to both control and treat the disease on January 12 at 12 pm. Webcast Link

ShowHide Related Items >><<
CANF Can-Fite BioPharma
$1.95 /

+0.045 (+2.36%)

Conference/Events
Force Welath to hold a webinar » 09:24
01/12/21
01/12
09:24
01/12/21
09:24
CANF

Can-Fite BioPharma

$1.91 /

+0.015 (+0.79%)

Webinar entitled,…

Webinar entitled, "NASH: The Biggest Market Opportunity of 2021" consists of Can-Fite BioPharma's Dr. Fishman discussing NASH, Non-Alcoholic Fatty Liver Disease and Hepatitis C, its implications on public health and the opportunities to both control and treat the disease on January 12 at 12 pm. Webcast Link

ShowHide Related Items >><<
CANF Can-Fite BioPharma
$1.91 /

+0.015 (+0.79%)

Hot Stocks
Can-Fite BioPharma announces Namodenoson study published » 07:09
01/08/21
01/08
07:09
01/08/21
07:09
CANF

Can-Fite BioPharma

$1.88 /

+0.005 (+0.27%)

Can-Fite BioPharma…

Can-Fite BioPharma announced a scientific paper titled, "Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial" was published in the peer reviewed journal Cancers. The paper highlights and analyzes results from Can-Fite's Phase II study, a randomized placebo-controlled trial to investigate Namodenoson as a 2nd-line treatment for advanced hepatocellular carcinoma, or HCC, and moderate hepatic dysfunction, as defined by Child-Pugh B, or CPB, scores of 7-9. Even though the trial did not meet its primary endpoint, in patients with a CPB score of 7, Namodenoson was associated with a significant improvement in 12-month overall survival and two patients are still under treatment for more than 3.5 years. A pivotal Phase III study of Namodenoson as a 2nd or 3rd line treatment in HCC CPB7 patients has been designed, and both the FDA and the European Medicines Agency, or EMA, have agreed with the protocol. Upon successful results, the trial may lead to concurrent marketing approval in the U.S. and Europe.

ShowHide Related Items >><<
CANF Can-Fite BioPharma
$1.88 /

+0.005 (+0.27%)

Over a month ago
Hot Stocks
Can-Fite receives Israel Ministry of Health approval to study cannabinoids » 07:07
12/15/20
12/15
07:07
12/15/20
07:07
CANF

Can-Fite BioPharma

$1.95 /

-0.02 (-1.02%)

Can-Fite BioPharma…

Can-Fite BioPharma announced it has received approval from the medical cannabis unit of Israel's Ministry of Health to conduct pre-clinical studies on the effect of nanomolar concentrations of cannabinoid fractions on the proliferation and functionality of cancer, inflammatory and adipocyte cells. This regulatory approval clears Can-Fite to advance its cannabinoid program by evaluating the effect of cannabis fractions at nanomolar concentrations binding with the A3 adenosine receptor, or A3AR, the target of the company's technology, in a broad range of diseases including cancer, inflammatory diseases, and metabolic diseases associated with fat accumulation. Can-Fite's recent findings show that cannabinoids can be clinically effective at minute concentrations, thereby potentially delivering efficacy without the adverse effect seen to occur with high cannabinoid concentrations as evidenced in the scientific literature. Prior pre-clinical studies jointly conducted by Can-Fite and Univo Pharmaceuticals demonstrate cannabinoid fractions inhibited liver cancer cell proliferation via A3AR.

ShowHide Related Items >><<
CANF Can-Fite BioPharma
$1.95 /

-0.02 (-1.02%)

Hot Stocks
Can-Fite BioPharma updates prgress with Namodenoson candidate in NAFLD » 07:19
12/14/20
12/14
07:19
12/14/20
07:19
CANF

Can-Fite BioPharma

$1.96 /

+0.07 (+3.70%)

Can-Fite BioPharma …

Can-Fite BioPharma announced the following progress with its Namodenoson drug candidate for non-alcoholic steatohepatitis, NASH, treatment: The Company is currently engaged in the design of a Phase IIb study for Namodenoson in the treatment of NASH. The protocol is being developed in conjunction with leading Key Opinion Leaders in NASH and liver diseases including Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom were involved in the design of Namodenoson's successfully completed Phase II study in NAFLD/NASH which achieved its efficacy endpoints. Drug supply - Manufacturing of Namodenoson for the upcoming clinical study has been completed. NASH patents were issued by the U.S. & European patent offices. Can-Fite's NASH clinical program is now protected by claims covering the use of the A3 adenosine receptor , the target of Can-Fite's platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested in nonalcoholic fatty liver disease, NAFLD, and NASH. Namodenoson for the treatment of NASH is licensed for distribution in Korea and China in deals that include upfront and milestone payments. "We accumulated very important and encouraging data from our well-designed former Phase II study which successfully met its endpoints with 60 patients and determined the optimal dosage. The Phase IIb NASH protocol will dose patients with 25 mg Namodenoson and will measure several safety and efficacy endpoints including liver biopsy," stated Can-Fite CEO Dr. Pnina Fishman.

ShowHide Related Items >><<
CANF Can-Fite BioPharma
$1.96 /

+0.07 (+3.70%)

Hot Stocks
Can-Fite presents NASH Phase II Namodenoson da at AASLD conference » 07:10
11/16/20
11/16
07:10
11/16/20
07:10
CANF

Can-Fite BioPharma

$1.81 /

+ (+0.00%)

Can-Fite…

Can-Fite BioPharmannounced that Dr. Rifaat Safadi, Principal Investigator of the Company's Phase II study of Namodenoson in the treatment of NAFLD/NASH delivered a late-breaking oral presentation at the AASLD conference, The Liver Meeting Digital Experience 2020. Titled "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety Of Namodenoson , An A3 Adenosine Receptor (Agonist, In Treating Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis " the oral presentation was given on Sunday, November 15 by Dr. Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel. Titled "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety Of Namodenoson (CF102), An A3 Adenosine Receptor (A3AR) Agonist, In Treating Non-Alcoholic Fatty Liver Disease (NAFLD) And Non-Alcoholic Steatohepatitis (NASH)" the oral presentation was given on Sunday, November 15 by Dr. Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel.

ShowHide Related Items >><<
CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 04:55
11/16/20
11/16
04:55
11/16/20
04:55
ALBO

Albireo Pharma

$35.35 /

+0.83 (+2.40%)

, AZN

AstraZeneca

$57.37 /

+0.54 (+0.95%)

, BMY

Bristol-Myers

$63.63 /

+0.88 (+1.40%)

, CANF

Can-Fite BioPharma

$1.81 /

+ (+0.00%)

, CBAY

CymaBay

$8.19 /

+0.18 (+2.25%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.79 /

+0.085 (+4.99%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.15 /

-0.08 (-0.40%)

, GSK

GlaxoSmithKline

$38.30 /

+0.55 (+1.46%)

, IVA

Inventiva

$14.01 /

+1 (+7.69%)

, MDGL

Madrigal Pharmaceuticals

$127.62 /

+2.61 (+2.09%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$81.10 /

+1.26 (+1.58%)

, MTCH

Match Group

$131.60 /

+0.22 (+0.17%)

, NVCR

Novocure

$124.46 /

+1 (+0.81%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$14.01 /

+1 (+7.69%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$81.10 /

+1.26 (+1.58%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.60 /

+0.22 (+0.17%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$124.46 /

+1 (+0.81%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 04:55
11/15/20
11/15
04:55
11/15/20
04:55
ALBO

Albireo Pharma

$35.35 /

+0.83 (+2.40%)

, AZN

AstraZeneca

$57.37 /

+0.54 (+0.95%)

, BMY

Bristol-Myers

$63.63 /

+0.88 (+1.40%)

, CANF

Can-Fite BioPharma

$1.81 /

+ (+0.00%)

, CBAY

CymaBay

$8.19 /

+0.18 (+2.25%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.79 /

+0.085 (+4.99%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.15 /

-0.08 (-0.40%)

, GSK

GlaxoSmithKline

$38.30 /

+0.55 (+1.46%)

, IVA

Inventiva

$14.01 /

+1 (+7.69%)

, MDGL

Madrigal Pharmaceuticals

$127.62 /

+2.61 (+2.09%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$81.10 /

+1.26 (+1.58%)

, MTCH

Match Group

$131.60 /

+0.22 (+0.17%)

, NVCR

Novocure

$124.46 /

+1 (+0.81%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$14.01 /

+1 (+7.69%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$81.10 /

+1.26 (+1.58%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.60 /

+0.22 (+0.17%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$124.46 /

+1 (+0.81%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 04:55
11/14/20
11/14
04:55
11/14/20
04:55
ALBO

Albireo Pharma

$35.35 /

+0.83 (+2.40%)

, AZN

AstraZeneca

$57.37 /

+0.54 (+0.95%)

, BMY

Bristol-Myers

$63.63 /

+0.88 (+1.40%)

, CANF

Can-Fite BioPharma

$1.81 /

+ (+0.00%)

, CBAY

CymaBay

$8.19 /

+0.18 (+2.25%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.79 /

+0.085 (+4.99%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.15 /

-0.08 (-0.40%)

, GSK

GlaxoSmithKline

$38.30 /

+0.55 (+1.46%)

, IVA

Inventiva

$14.01 /

+1 (+7.69%)

, MDGL

Madrigal Pharmaceuticals

$127.62 /

+2.61 (+2.09%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$81.10 /

+1.26 (+1.58%)

, MTCH

Match Group

$131.60 /

+0.22 (+0.17%)

, NVCR

Novocure

$124.46 /

+1 (+0.81%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

+ (+0.00%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$14.01 /

+1 (+7.69%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$81.10 /

+1.26 (+1.58%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.60 /

+0.22 (+0.17%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$124.46 /

+1 (+0.81%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$124.46 /

+1 (+0.81%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$127.62 /

+2.61 (+2.09%)

IVA Inventiva
$14.01 /

+1 (+7.69%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

EXEL Exelixis
$20.15 /

-0.08 (-0.40%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

ALBO Albireo Pharma
$35.35 /

+0.83 (+2.40%)

MTCH Match Group
$131.60 /

+0.22 (+0.17%)

MRK Merck
$81.10 /

+1.26 (+1.58%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$38.30 /

+0.55 (+1.46%)

DRRX Durect
$1.79 /

+0.085 (+4.99%)

CBAY CymaBay
$8.19 /

+0.18 (+2.25%)

BMY Bristol-Myers
$63.63 /

+0.88 (+1.40%)

AZN AstraZeneca
$57.37 /

+0.54 (+0.95%)

Conference/Events
American Association for Study of Liver Diseases to hold a virtual meeting » 08:58
11/13/20
11/13
08:58
11/13/20
08:58
ALBO

Albireo Pharma

$34.60 /

+0.46 (+1.35%)

, AZN

AstraZeneca

$56.84 /

-1.155 (-1.99%)

, BMY

Bristol-Myers

$62.74 /

-0.68 (-1.07%)

, CANF

Can-Fite BioPharma

$1.81 /

-0.225 (-11.06%)

, CBAY

CymaBay

$8.03 /

+0.07 (+0.88%)

, DNA

Bought by RHHBY

$0.00 /

+ (+0.00%)

, DRRX

Durect

$1.71 /

-0.06 (-3.40%)

, ESALY

Eisai

$0.00 /

+ (+0.00%)

, EXEL

Exelixis

$20.23 /

-0.46 (-2.22%)

, GSK

GlaxoSmithKline

$37.75 /

-0.4281 (-1.12%)

, IVA

Inventiva

$13.01 /

-0.745 (-5.42%)

, MDGL

Madrigal Pharmaceuticals

$128.00 /

+1.92 (+1.52%)

, MNK

Mallinckrodt

$0.00 /

+ (+0.00%)

, MRK

Merck

$79.84 /

-1.22 (-1.51%)

, MTCH

Match Group

$131.39 /

-2.04 (-1.53%)

, NVCR

Novocure

$123.46 /

+0.9 (+0.73%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

AASLD 2020: The Virtual…

AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link

ShowHide Related Items >><<
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$123.46 /

+0.9 (+0.73%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

IVA Inventiva
$13.01 /

-0.745 (-5.42%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

CANF Can-Fite BioPharma
$1.81 /

-0.225 (-11.06%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

09/10/20 Cowen
Albireo Pharma price target raised to $65 from $39 at Cowen
09/09/20 Guggenheim
Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim
09/08/20 William Blair
William Blair says Albireo data confirms 'best-in-class' profile for odevixibat
09/08/20 Jefferies
Albireo Pharma price target raised to $79 from $50 at Jefferies
AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

11/11/20 Oppenheimer
Amgen price target raised to $280 from $275 at Oppenheimer
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
11/11/20 HSBC
AstraZeneca upgraded to Hold from Reduce at HSBC
10/23/20 Stifel
FibroGen safety data mitigates concerns of roxadustat black box, says Stifel
BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein
11/10/20 Bernstein
Bristol-Myers initiated with a Market Perform at Bernstein
11/06/20 Gabelli
Bristol-Myers downgraded to Hold from Buy at Gabelli
11/05/20 BofA
BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down
CANF Can-Fite BioPharma
$1.81 /

-0.225 (-11.06%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

11/06/20 Raymond James
CymaBay price target raised to $12 at Raymond James after Q3 report
09/25/20 Piper Sandler
CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler
09/09/20 B. Riley Securities
CymaBay price target raised to $13 from $9 at B. Riley FBR
08/27/20 Piper Sandler
Piper Sandler 'astonished' by seladelpar's long-term benefits
DNA Bought by RHHBY
$0.00 /

+ (+0.00%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

11/03/20 Chardan
Durect Covid trial update increased interest in program, says Chardan
10/30/20
Fly Intel: Top five analyst initiations
10/30/20 Chardan
Durect initiated with a Buy at Chardan
10/20/20 Cantor Fitzgerald
Durect assumed with an Overweight at Cantor Fitzgerald
ESALY Eisai
$0.00 /

+ (+0.00%)

11/05/20 Jefferies
Eisai upgraded to Buy from Hold at Jefferies
09/08/20 Jefferies
Eisai downgraded to Hold from Buy at Jefferies
EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

10/26/20 Piper Sandler
Exelixis could have successor to Cabometyx with XL092, says Piper Sandler
09/22/20 Morgan Stanley
Exelixis price target raised to $29 from $23 at Morgan Stanley
09/21/20 Piper Sandler
Exelixis price target raised to $33 from $30 at Piper Sandler
06/30/20 Piper Sandler
Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler
GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

11/13/20 Morgan Stanley
GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley
11/02/20 Liberum
GlaxoSmithKline upgraded to Buy from Hold at Liberum
10/30/20 Barclays
GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays
10/27/20 Truist
AnaptysBio price target raised to $27 from $20 at Truist
IVA Inventiva
$13.01 /

-0.745 (-5.42%)

10/13/20 Roth Capital
Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation
08/17/20 H.C. Wainwright
Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright
08/05/20
Fly Intel: Top five analyst initiations
08/05/20 Roth Capital
Inventiva initiated with a Buy at Roth Capital
MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

11/06/20 Goldman Sachs
Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs
11/06/20 Piper Sandler
Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting
11/06/20 H.C. Wainwright
Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright
11/05/20 Piper Sandler
Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler
MNK Mallinckrodt
$0.00 /

+ (+0.00%)

08/06/20 Citi
Mallinckrodt price target lowered to $1 from $2 at Citi
08/05/20 BMO Capital
Mallinckrodt price target lowered to $2 from $4 at BMO Capital
08/04/20 Piper Sandler
Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler
07/14/20 BMO Capital
Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital
MRK Merck
$79.84 /

-1.22 (-1.51%)

11/10/20 Bernstein
Bernstein bullish on Merck, initiates with an Outperform
11/10/20 Bernstein
Merck initiated with an Outperform at Bernstein
11/02/20 Raymond James
Jounce Therapeutics downgraded to Market Perform at Raymond James
10/23/20
Fly Intel: Pre-market Movers
MTCH Match Group
$131.39 /

-2.04 (-1.53%)

11/10/20 Truist
Match Group price target raised to $150 from $125 at Truist
11/10/20 Deutsche Bank
Match Group price target raised to $160 from $150 at Deutsche Bank
11/09/20 Citi
Match Group price target raised to $160 from $135 at Citi
09/24/20 Jefferies
Match Group positioned to take advantage of pent up demand, says Jefferies
NVCR Novocure
$123.46 /

+0.9 (+0.73%)

10/30/20 Mizuho
Novocure price target raised to $150 from $84 at Mizuho
10/29/20 Piper Sandler
Novocure price target raised to $140 from $125 at Piper Sandler
10/05/20 Piper Sandler
Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler
09/23/20
Fly Intel: Top five analyst initiations
RHHBY Roche
$0.00 /

+ (+0.00%)

11/11/20 Truist
Opthea initiated with a Buy at Truist
10/16/20 UBS
Roche price target lowered to CHF 370 from CHF 390 at UBS
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
09/29/20 Berenberg
Roche initiated with a Hold at Berenberg
RHHBY Roche
$0.00 /

+ (+0.00%)

NVCR Novocure
$123.46 /

+0.9 (+0.73%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

  • 10
    Sep
  • 10
    Jul
  • 30
    Jan
  • 11
    Dec
RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

RHHBY Roche
$0.00 /

+ (+0.00%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

MDGL Madrigal Pharmaceuticals
$128.00 /

+1.92 (+1.52%)

IVA Inventiva
$13.01 /

-0.745 (-5.42%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

EXEL Exelixis
$20.23 /

-0.46 (-2.22%)

ESALY Eisai
$0.00 /

+ (+0.00%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

ALBO Albireo Pharma
$34.60 /

+0.46 (+1.35%)

MTCH Match Group
$131.39 /

-2.04 (-1.53%)

MRK Merck
$79.84 /

-1.22 (-1.51%)

MNK Mallinckrodt
$0.00 /

+ (+0.00%)

GSK GlaxoSmithKline
$37.75 /

-0.4281 (-1.12%)

DRRX Durect
$1.71 /

-0.06 (-3.40%)

CBAY CymaBay
$8.03 /

+0.07 (+0.88%)

BMY Bristol-Myers
$62.74 /

-0.68 (-1.07%)

AZN AstraZeneca
$56.84 /

-1.155 (-1.99%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.